Carcinoma ex pleomorphic adenoma (CXPA) is an aggressive epithelial and/or myoepithelial neoplasm that arises in association with a pleomorphic adenoma (PA). Its etiopathogenesis remains poorly understood, but it is believed that the development of this tumor is due to the accumulation of genetic, protein, metabolic, and epigenetic alterations in a PA. A retrospective review of the Salivary Gland Tumor Registry in Pilsen yielded 84 CXPA, namely 25/84 salivary duct carcinoma (SDC), 15/84 myoepithelial carcinoma (MC), 1/84 epithelial-myoepithelial carcinoma (EMC), and 1/84 adenoid cystic carcinoma (AdCC). All 84 CXPA cases were analyzed by next-generation sequencing (NGS) and/or fluorescence in situ hybridization (FISH). Forty-three tumors originally diagnosed as CXPA (43/84, 51.2%) showed some molecular alteration. Fusion transcripts were identified in 12/16 (75%) CXPA, including LIFR::PLAG1, CTNNB1::PLAG1, FGFR1::PLAG1 , and a novel fusion, HMGA2::LINC02389 . Most of the fusions were confirmed by FISH using PLAG1 (6/11) and HMGA2 (1/1) gene break probes. Split signals indicating gene break were identified by FISH for PLAG1 (12/17), HMGA2 (3/4), EWSR1 (7/22), and MYB (2/7). Concerning pathogenic mutations, only CXPA with epithelial differentiation (SDC) presented these alterations, including HRAS mutation (2/4), TP53 (1/4), PTEN (1/4), and ATK1 (1/4). In addition, amplifications in ERBB2 (17/35), MDM2 (1/4), and EWSR1 (1/7) were detected. A novel finding was the discovery of an HMGA2::LINC02389 fusion in 1 patient with EMC ex-PA. The present results indicate that molecular profiling of CXPA with myoepithelial differentiation (MC) tends to reveal chromosomal fusion events, whereas CXPA with epithelial differentiation (SDC) tends to have a higher frequency of pathogenic mutations and gene amplifications.

Bioptic Laboratory Ltd

Department of Oral Diagnosis Piracicaba Dental School University of Campinas Piracicaba

Department of Pathology Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Pathology Institute of Biomedicine University of Turku Turku Finland

Department of Pathology School of Medical Sciences University of Campinas Campinas São Paulo Brazil

See more in PubMed

World Health Organization. WHO Classification of Head and neck tumours, 5th ed. Lyon (France): International Agency for Research on Cancer; 2022. https://tumourclassification.iarc.who.int/chapters/52

Mariano FV, Noronha ALF, Gondak RO, et al. Carcinoma ex pleomorphic adenoma in a Brazilian population: clinico-pathological analysis of 38 cases. Int J Oral Maxillofac Surg. 2013;42:685–692.

Di Palma S. Carcinoma ex pleomorphic adenoma, with particular emphasis on early lesions. Head Neck Pathol. 2013;7(suppl 1):S68–S76.

Altemani A, Martins MT, Freitas L, et al. Carcinoma ex pleomorphic adenoma (CXPA): immunoprofile of the cells involved in carcinomatous progression. Histopathology. 2005;46:635–641.

de Lima-Souza RA, Scarini JF, Egal ESA, et al. Secretory carcinoma ex pleomorphic adenoma of the submandibular gland: an immunohistochemical study. Oral Oncol. 2021;120:105262.

Gupta A, Koochakzadeh S, Neskey DM, et al. Carcinoma ex pleomorphic adenoma: a review of incidence, demographics, risk factors, and survival. Am J Otolaryngol. 2019;40:102279.

de Lima‐Souza RA, Scarini JF, Lavareze L, et al. Discovery proteomics reveals potential protein signature associated with malignant phenotype acquisition in pleomorphic adenoma. Oral Dis. 2023;29:1017–1027.

Mariano FV, Fidalgo F, Casarim ALM, et al. Somatic copy number alterations in pleomorphic adenoma and recurrent pleomorphic adenoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020;129:59–64.

de Lima-Souza RA, Rodrigues N, de M, et al. Metabolic alterations in carcinoma ex pleomorphic adenoma development of lacrimal glands. Int Ophthalmol. 2022;42:1101–1109.

Skálová A, Hyrcza MD, Vaneček T, et al. Fusion-positive salivary gland carcinomas. Genes Chromosomes Cancer. 2022;61:228–243.

Skálová A, Vanecek T, Sima R, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010;34:599–608.

Agaimy A, Ihrler S, Baněčková M, et al. HMGA2-WIF1 rearrangements characterize a distinctive subset of salivary pleomorphic adenomas with prominent trabecular (canalicular adenoma-like) morphology. Am J Surg Pathol. 2022;46:190–199.

Skálová A, Vanecek T, Uro-Coste E, et al. Molecular profiling of salivary gland intraductal carcinoma revealed a subset of tumors harboring NCOA4-RET and novel TRIM27-RET fusions. Am J Surg Pathol. 2018;42:1445–1455.

Baněčková M, Uro-Coste E, Ptáková N, et al. What is hiding behind S100 protein and SOX10 positive oncocytomas? Oncocytic pleomorphic adenoma and myoepithelioma with novel gene fusions in a subset of cases. Hum Pathol. 2020;103:52–62.

Skálová A, Agaimy A, Vanecek T, et al. Molecular profiling of clear cell myoepithelial carcinoma of salivary glands with EWSR1 rearrangement identifies frequent PLAG1 gene fusions but no EWSR1 fusion transcripts. Am J Surg Pathol. 2021;45:1–13.

Skálová A, Weinreb I, Hyrcza M, et al. Clear cell myoepithelial carcinoma of salivary glands showing EWSR1 rearrangement. Am J Surg Pathol. 2015;39:338–348.

Santana T, Pavel A, Martinek P, et al. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications. Hum Pathol. 2019;93:37–47.

Takase S, Kano S, Tada Y, et al. Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification. Oncotarget. 2017;8:59023–59035.

Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med. 2018;142:1364–1382.

Šteiner P, Andreasen S, Grossmann P, et al. Prognostic significance of 1p36 locus deletion in adenoid cystic carcinoma of the salivary glands. Virchows Arch. 2018;473:471–480.

Michal M, Agaimy A, Contreras AL, et al. Dysplastic lipoma: a distinctive atypical lipomatous neoplasm with anisocytosis, focal nuclear atypia, p53 overexpression, and a lack of MDM2 gene amplification by FISH; a report of 66 cases demonstrating occasional multifocality and a rare association Wi. Am J Surg Pathol. 2018;42:1530–1540.

Chiosea SI, Thompson LDR, Weinreb I, et al. Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations. Cancer. 2016;122:3136–3144.

Mueller SA, Gauthier M-EA, Blackburn J, et al. Molecular patterns in salivary duct carcinoma identify prognostic subgroups. Mod Pathol. 2020;33:1896–1909.

Voz ML, Mathys J, Hensen K, et al. Microarray screening for target genes of the proto-oncogene PLAG1. Oncogene. 2004;23:179–191.

Voz ML, Agten NS, Van de Ven WJ, et al. PLAG1, the main translocation target in pleomorphic adenoma of the salivary glands, is a positive regulator of IGF-II. Cancer Res. 2000;60:106–113.

Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer. 2007;7:899–910.

Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 2007;21:1025–1030.

Bubola J, MacMillan CM, Demicco EG, et al. Targeted RNA sequencing in the routine clinical detection of fusion genes in salivary gland tumors. Genes Chromosom Cancer. 2021;60:695–708.

Ihrler S, Stiefel D, Jurmeister P, et al. Salivary carcinosarcoma: insight into multistep pathogenesis indicates uniform origin as sarcomatoid variant of carcinoma ex pleomorphic adenoma with frequent heterologous elements. Histopathology. 2023;82:576–586.

Lin J, Chen L, Zhang D. Long non-coding RNA LINC-PINT as a novel prognostic biomarker in human cancer: a meta-analysis and machine learning. Sci Rep. 2024;14:7483.

Cui D, Li Z, Wei C, et al. Long non-coding RNA LINC00491 accelerates head and neck squamous cell carcinoma progression through regulating miR-508-3p/SATB1 axis and activating Wnt signaling pathway. Cytokine. 2024;175:156444.

Witte HM, Gebauer N, Steinestel K. Mutational and immunologic Landscape in malignant salivary gland tumors harbor the potential for novel therapeutic strategies. Crit Rev Oncol Hematol. 2022;170:103592.

Dogan S, Xu B, Rana S, et al. Loss of CDKN2A/B is a molecular marker of high-grade histology and is associated with aggressive behavior in acinic cell carcinoma. Mod Pathol. 2023;36:100150.

Padhi SS, Roy S, Kar M, et al. Role of CDKN2A/p16 expression in the prognostication of oral squamous cell carcinoma. Oral Oncol. 2017;73:27–35.

Anzick SL, Chen W-D, Park Y, et al. Unfavorable prognosis of CRTC1-MAML2 positive mucoepidermoid tumors with CDKN2A deletions. Genes Chromosom Cancer. 2010;49:59–69.

Basu A, Lambring CB. Akt isoforms: a family affair in breast cancer. Cancers. 2021;13:3445.

Dalin MG, Desrichard A, Katabi N, et al. Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer. Clin Cancer Res. 2016;22:4623–4633.

Luk PP, Weston JD, Yu B, et al. Salivary duct carcinoma: clinicopathologic features, morphologic spectrum, and somatic mutations. Head Neck. 2016;38(suppl 1):E1838–E1847.

Wang K, Russell JS, McDermott JD, et al. Profiling of 149 salivary duct carcinomas, carcinoma ex pleomorphic adenomas, and adenocarcinomas, not otherwise specified reveals actionable genomic alterations. Clin Cancer Res. 2016;22:6061–6068.

Ferguson DC, Momeni Boroujeni A, Zheng T, et al. ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing. Mod Pathol. 2022;35:895–902.

Hennigs A, Riedel F, Gondos A, et al. Prognosis of breast cancer molecular subtypes in routine clinical care: a large prospective cohort study. BMC Cancer. 2016;16:734.

Nishijima T, Yamamoto H, Nakano T, et al. Dual gain of HER2 and EGFR gene copy numbers impacts the prognosis of carcinoma ex pleomorphic adenoma. Hum Pathol. 2015;46:1730–1743.

Fujimi A, Nagamachi Y, Yamauchi N, et al. Eribulin in combination with HER2-targeted antibodies for successful treatment of metastatic salivary duct carcinoma: a report of two cases. Oral Oncol. 2021;120:105287.

Yu W, Ding C, Li K. Partial response to RC-48 as palliative treatment in a patient with locallocally advanced carcinoma ex pleomorphic adenoma harboring a HER2 mutation: a case report. Oral Oncol. 2023;146:106541.

Thway K, Fisher C. Mesenchymal tumors with EWSR1 gene rearrangements. Surg Pathol Clin. 2019;12:165–190.

Fisher C. The diversity of soft tissue tumours with EWSR1 gene rearrangements: a review. Histopathology. 2014;64:134–150.

Antonescu CR, Zhang L, Chang NE, et al. EWSR1-POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty-six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene. Genes Chromosom Cancer. 2010;49:1114–1124.

Stenman G. Fusion oncogenes in salivary gland tumors: molecular and clinical consequences. Head Neck Pathol. 2013;7:12–19.

Brill LB, Kanner WA, Fehr A, et al. Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms. Mod Pathol. 2011;24:1169–1176.

Lee JH, Kang HJ, Yoo CW, et al. PLAG1, SOX10, and Myb expression in benign and malignant salivary gland neoplasms. J Pathol Transl Med. 2019;53:23–30.